Tufts: Personalized medicines trend gains traction; Bioniche nabs $4M milestone

> That personalized medicine trend you've been hearing so much about isn't just a bunch of hype. A new study from the Tufts Center for the Study of Drug Development concludes that the personalized drug development strategy is a key feature among biopharma companies. And an increased use of biomarkers to gauge patient response to these drugs is a common feature--even though stiff regulatory challenges remain. Report

> A British group in search of a gastrointestinal cancer vaccine has partnered with London Genetics Limited to seek out a set of biomarkers which will allow investigators to clearly define a population of patients who can benefit from it. Story

> Bioniche Life Sciences nabbed a $4 million milestone payment from its development partner, Endo Pharmaceuticals. This milestone is the fourth achieved by Bioniche subsequent to the parties executing their agreement in July, 2009. Bioniche release

> The Ares Life Sciences fund plans to buy out all the shares of Stallergenes it doesn't already own. Story

> Using a well-known colorectal tumor tissue biomarker, researchers were able to track the efficacy of a commonly used gout drug against precancerous polyps that frequently go on to trigger lethal cases of colon cancer. Article

> Xenon Pharmaceuticals is partnering with Isis Pharmaceuticals to develop RNA-targeting drugs for anemia. No financial details were released. Item

> In an effort to drum up fresh funds Hungary is expected to change the write-off rules for pharma R&D, a switch which could hit Egis and Richter. Story

> Accentia Biopharmaceuticals and its subsidiary Biovest have exited Chapter 11. News

And Finally... Middle aged women who drink a moderate amount--one or two alcoholic drinks a day--stand a much better chance of staying healthy well into old age. Story

Suggested Articles

WuXi names Dong to helm new vaccines CDMO; Paragon appoints Jimenez as capital makers lead; Levy joins Spark as CMO.

The phase 1 and 2 results suggest the vaccine may be safe, tolerable and capable of triggering production of antibodies against the coronavirus.

The platform, which is in use at companies including Agios, enables researchers to simultaneously detect DNA and protein changes in single cells.